Technetium (99mTc) votumumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | tumor antigen CTAA16.88 |
Clinical data | |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
![]() ![]() |
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1][2] It was developed for the detection of colorectal tumors, but has never been marketed.[3]
The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.[4]
References
[edit]- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
- ^ Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
- ^ "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10.
Non-renewal of the marketing authorisation in the European Union
- ^ "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).